On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > REGULATORY
REGULATORY
- MHLW Warns of Severe Febrile Neutropenia for Cabazitaxel
January 30, 2015
- Drug Discovery Support Project for Academia to Receive 3-Fold Budget Increase in FY2015
January 30, 2015
- Chuikyo’s HTA Panel Holds First Closed-Door Meeting
January 29, 2015
- Expenditure for Senshin-Iryo Services Totaled 17.4 Billion Yen: MHLW
January 29, 2015
- Chuikyo Approves Insurance Reimbursement for Companion Diagnostic for Zelboraf
January 29, 2015
- Government Releases Strategy for Dementia
January 28, 2015
- Prof. Hashida of Kyoto University Elected as PAFSC Chairman
January 28, 2015
- Panel OKs Requirements to Give Legal Status to Clinical Research Core Hospitals
January 27, 2015
- Panel on Unapproved Drugs Weighs Revamp upon Rollout of New Development Request Scheme
January 27, 2015
- Editor’s Pick: Five Healthcare News Headlines for Jan. 12 - 25
January 26, 2015
- Japan-Version Compassionate Use May Cover Drugs with No Approval Globally
January 26, 2015
- Council OKs Application Based on Info in Public Domain for Taxol Once Weekly for 3 Weeks for Gastric Cancer
January 26, 2015
- PMDA Evaluating Apixaban for Risk of Interstitial Pneumonia
January 26, 2015
- Government Launches Genomic Medicine Panel
January 23, 2015
- Chuikyo’s HTA Panel to Hold Closed Meeting on Jan. 28
January 23, 2015
- NIBIO Chief Pins Hopes on Potential Synergies from Impending Merger
January 22, 2015
- NIBIO Completes Development of Prototype Adjuvant Database
January 22, 2015
- PAFSC’s Second Committee on Drugs Recommends Approval for Eisai’s Lenvatinib
January 22, 2015
- R&D Tax Credit Revamp (2): No Deadline Set, yet Revision Could Come Up for Debate towards FY2017
January 21, 2015
- Health Ministry Reveals Guidelines on Research Misconduct
January 20, 2015
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…